Hepatocellular Cancer Treatment

Guest Editor:

**Prof. Dr. Renuka Iyer**
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
Renuka.Iyer@RoswellPark.org

Deadline for manuscript submissions: closed (15 July 2019)

**Message from the Guest Editor**

Dear Colleagues,

Progress in hepatocellular cancer has been remarkable in the last year after a decade of unsuccessful trials. Besides great strides in treating hepatitis C, we now have a number of molecularly targeted drugs and immunotherapies, and the best treatment option and sequence for advanced patients is evolving. Early detection, optimal selection of candidates for surgery, and liver-directed therapies remain challenging. This Special Issue will discuss important basic science developments in our understanding of liver cancer biology; innovations in the treatment of localized disease; and novel therapeutics, especially immunotherapy agents and upcoming trials that may impact the treatment of hepatocellular cancer in the years to come.

Prof. Dr. Renuka Iyer
Guest Editor

mdpi.com/si/22110
Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

**Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

**Contact Us**

Cancers  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com  
mdpi.com/journal/cancers  
cancers@mdpi.com  
@Cancers_MDPI